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A set of 150 synthetic peptides spanning the proteins NS3-NS4-NS5 of the hepatitis C virus (HCV) was synthesized 
and tested with a panel of 20 sera obtained from HCV-infected patients. Of 62 peptides prepared from the NS3 region, 
none exhibited strong antigenic reactivity. Rather, five peptides from this region demonstrated specific reactivity with only 
5-10% of antFHCV-positive sera. Nonetheless, it is well known that the NS3 region contains strong antigenic epitopes. 
These epitopes appear to be modeled in a functionally active manner with recombinant proteins and cannot be mimicked 
properly with short synthetic peptides. This finding suggests that the major NS3 antigenic epitopes are conformationally 
dependent. Seven of 20 peptides prepared from the NS4 region were immunoreactive. Five peptides from this region 
demonstrated very strong HOV-specific antigenic reactivity. Four of the five peptides belong to the recognized immunoreac- 
tive 5-1-1 region located inside the C100-3 antigen. One peptide demonstrating immunoreactivity with approximately 90% 
of anti-HOV-positive sera was found outside the C100-3 region at the C-terminal part of the NS4 protein. Of 68 peptides 
synthesized from the NS5 protein, 30 were immunoreactive. Six of the 30 demonstrated immunoreactivity with 35-50% of 
anti-HCV-positive sera. Thus, the NS4 and NS5 regions of the HCV polyprotein contain a large number of specific, broadly 
reactive, linear antigenic epitopes. The highly antigenic reactivity of the NS5 region suggests that this protein may have 
significant diagnostic potential. © 199B Academic Press, Inc. 
The hepatitis C virus (HCV) is the major causative 
agent of parenterally transmitted non-A, non-B hepatitis 
worldwide (1). Recent progress in the identification, clon- 
ing, and sequencing of the HOV genome (2) allowed for 
the elucidation of the genomic organization of this virus. 
The HCV genome is a positive RNA molecule that shares 
homology with flavivirus and pestivirus (3). The complete 
primary structure of the genome from several HOV iso- 
lates is known (4- 13). Preparation of HCV-specific cDNA 
has accelerated the development of diagnostic test sys- 
tems for the identification of serologic markers of this 
infection. Among the most important diagnostic reagents 
for the detection of anti-HCV-specific activity in sera were 
the 033 and C100-3 recombinant polypeptides derived 
from the nonstructural proteins of NS3 and NS4, respec- 
tively (14, 15). The structural proteins, especially the nu- 
cleocapsid protein C, also contain broadly reactive anti- 
genic epitopes (16-20) and have been included in vari- 
ous test systems (15, 16, 18, 21-24). Fragments of the 
NS5 protein expressed in Escherichia coil are immunore- 
active with sera obtained from HOV-infected individuals 
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(23, 25), a finding that suggests that this protein may 
also elicit diagnostically relevant antibodies. Therefore, 
almost all HOV-specific proteins have been reported to 
contain antigenic epitopes. The antigenic composition of 
the HCV structural proteins has been thoroughly charac- 
terized (18, 20, 26-30), whereas a complete analysis of 
the nonstructural proteins has not yet been published. 
Only few epitopes have been found in these proteins 
by using synthetic peptides (28, 31-33). To analyze the 
antigenic structure of the HOV nonstructural proteins, we 
prepared a set of 150 synthetic peptides spanning more 
than 90% of the NS3-NS4-NS5 region of the HCV poly- 
protei n (Fig. 1). All synthetic peptides were prepared us- 
ing the sequence of the HCV genome published by Kate 
et al. (4). Almost all the peptides were 20 amino acids 
(aa) long with only few exceptions when 19-mer peptides 
were synthesized. The NS3 protein was spanned with 
62 peptides, the NS4 protein with 20 peptides, and the 
NS5 protein with 68 peptides. When designing peptides 
for chemical synthesis, we paid special attention to re- 
gions known to contain antigenic reactivity, such as the 
O100-3, 5-1-1, and 033 regions (14, 15), or to regions 
with predicted but not yet confirmed antigenic reactivity, 
such as the entire NS5a and the C-terminal region of the 
NS6b. The number of peptides spanning different regions 
differed. In the NS3 protein, the region 1080-1313 aa 
was covered with 27 peptides, the region 1316-1456 aa 
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FiG. 1. Regions selected for the synthesis of peptides (shown by horizontal bJack bars) and the location of immunoreactive synthetic peptides 
(shown by small vertical bars) within the HCV nonstructural proteins NS3-NS4-NSS. Open vertical bars indicate weakly reactive peptides and 
closed vertical bars indicate relatively strong antigenically reactive peptides (for more detail, see Tables 1 and 2). 
with 15 peptides, and the region 1478-1657 aa with 20 
peptides. Two of the most thoroughly investigated re- 
gions of the NS4 protein are located at positions 1689- 
1789 aa and 1899-1980 aa and were spanned with 10 
and 5 peptides, respectively. Since the entire NS5a is 
relatively hydrophilic as predicted by the method by Kyte 
and Doolittle (34) and composed of mainly random coil 
or/~-turn structures as predicted by the method by Ptitsyn 
and Finkelstein (35), all of which are characteristics of 
antigenically active sites, this region was spanned with 
a large number of peptides. The region at position 1987- 
2083 aa was spanned with 8 peptides, the region at 
position 2150-2332 aa with 16 peptides, and the region 
at position 2336-2415 aa with 11 peptides. In the NS5b 
protein, a number of small scattered regions were se- 
lected for peptide synthesis. The most extended region 
covered with synthetic peptides is located at the C-termi- 
nus of the NS5b at position 2883-2990 aa. This region 
was spanned with 9 synthetic peptides. 
Peptides were synthesized by FMOC chemistry (36) on 
an ACT Model MPS 350 multiple peptide synthesizer (Ad- 
vanced Chemtech, Louisville, KY). After characterization by 
amino acid analysis, high performance liquid chromatogra- 
phy, and capillary electrophoresis, peptides were used di- 
rectly in enzyme immunoassay as described elsewhere 
(3/0. Briefly, synthetic peptides were adsorbed to microtiter 
wells (Immulon il, Dynatech Labs, Inc.) at a concentration 
of 5 #g per well and allowed to interact with human anti- 
HCV sera diluted 1,50 for 1 hr at 37 °. Antigenic activity of 
peptides was identified using affinity-purified antibodies to 
human IgG conjugated to horseradish peroxidase (Boeh- 
ringer-Mannheim, Indianapolis, IN). Peptides were judged 
immunoreactive if the P/N ratio was greater than 3.0, where 
P represents the optical density (OD) value at 490 nm ob- 
tained with an anti-HCV-positive specimen and N repre- 
sents the OD value of negative controls. A P/N ratio equal 
to 3 was equivalent to the mean OD values of negative 
control sera plus at least 3.5 standard deviations of the 
mean. Each peptide was individually analyzed at least three 
times with each of 20 anti-HCV-positive and 20 anti-HOV- 
negative sera. A cutoff was established individually for each 
peptide using all 20 anti-HCV-negative sera. It is important 
to note that among anti-HCV-negative sera, not a single 
specimen when analyzed with those peptides presented 
in Tables 1 and 2 exceeded the established cutoff value, 
indicating the absence of nonspecificity for these peptides. 
Typically, the OD value for negative controls was 0.02 + 
0.005. All serum samples were randomly selected from a 
collection of specimens reposited at the Hepatitis Branch, 
Centers for Disease Control and Prevention (Atlanta, GA). 
Anti-HOV-negative sera were obtained from normal blood 
donors. Anti-HCV-positive sera were collected from chroni- 
cally HCV-infected individuals. The anti-HOV status of all 
sera was identified with the second generation anti-HOV 
EIA (Abbott Laboratories, Chicago, IL) and confirmed with 
a semiautomated dot blot immunoassay (Abbott MATRIX, 
Abbott Laboratories, Chicago, iL). 
The results of the analysis of the anti-HOV reactivity 
of synthetic peptides are shown in Fig. 1 and Tables 1 
and 2. Despite the recognized strong antigenic reactivity 
of the NS3 protein, which has been confirmed by many 
investigators, we were unable to identify any broadly re- 
active peptides among the 62 peptides analyzed from 
this region. Five peptides from this region were identified 
as marginally reactive. These peptides reacted with only 
one or two anti-HCV-positive sera (Table 1). This result 
suggests that the NS3 antigenic epitopes can be effi- 
ciently modeled only by large recombinant proteins and 
are poorly mimicked within relatively short synthetic pep- 
tides. Epitopes located within the NS3 protein seem to 
be conformationally dependent. Of five immunoreactive 
peptides from the NS3 protein, only two peptides, 60 and 
117, are significantly overlapped (Table 1) and may share 
an antigenic epitope. Therefore, these data suggest the 
presence of four antigenic epitopes that may be modeled 
with synthetic peptides within the NS3 protein. However, 
there may be more than four antigenic sites within the 
IXIS3 region since some immunodominant epitopes within 
this region may have been neglected in our analysis. It 
is well known that synthetic peptides fail to reproduce 
topographic (discontinuous) antigenic epitopes, which 
compose in some cases more than 98% of all antigenic 
epitopes of a protein (38). Synthetic peptides of different 
sizes should be used to examine the fine antigenic struc- 
ture of the NS3 region. A recent study on the antigenic 
reactivity of two peptides derived from the NS3 protein 
demonstrated the existence of at least one additional 
epitope at position 1479-1497 aa (28). A synthetic pep- 
tide with a similar aa sequence (1478-1497 aa) was 
analyzed in our study. This peptide, however, did not 
demonstrate immunoreactivity. This discrepancy may be 
due to differences in sequences between HCV strains 
used for the synthesis of peptides or in the sera used 
for the analysis. 
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TABLE 1 
IMMUNQREACTIVE PEPTIDES FROM THE NS3 AND NS4 PROTEINS 
Region Peptide Location, aa Sequence Activity a P/N ° 
NS3 99 1126-1145 GSSDLYLVTRHADVlPVRRR 1/20 19.4 
90 1181 - 1200 RAAVCTRGVAKAVDFI PVEN 1/20 15.6 
107 1254-1273 LN PSVAATLG FGAYMSKAHG 2/20 3.5; 5.5 
117 1563-1582 TGLTHIDAHFLSQTKQSGEN 1/20 18.8 
60 1569-1588 DAH FLSQTKQSGEN LPYLVA 2/20 21.0; 24.5 
NS4 50 1689-1708. SGKPAIIPDREVLYREFDEM 8/20 21.8 (9.8-34.9) 
51 1691 - 1710 KPAIIPDREVLYREFDEMEE 9/20 17.3 (5.8-29.9) 
52 1701 - 1720 LYREFDEMEECSQHLPYIEQ 5/20 13.3 (4.7-22.8) 
53 1711-1730 CSQHCPYIEQGMMLAEQFKQ 9/20 12.6 (5.t --35.4) 
54 1721-1740 GMMLAEQFKQKALGLLQTAS 1/20 9.1 
57 1864-1886 VAFKIMSGEVPSTEDLVNLL 1/20 21.7 
59 1921 - 1940 AFASRGN HVSPTHYVPESDA 18/20 40.0 (5.3-85.5) 
The number of sera immunoreactive with synthetic peptides of 20 anti-HCV-positive serum specimens. 
For peptides reactive with two specimens, P/N is shown for both sera; for peptides reactive with more than two specimens, the mean of the 
P/N ratio for all reactive sera is presented with the range of P/N values shown in parentheses. 
TABLE 2 
IMMUNOREACTIVE PEPTIDES FROM THE ~85 PROTEIN 
Peptide Location, aa Sequence Activity ~ P/N b 
212 2032-2051 GAQITGHVKNGSMRIVGPKT 1/20 4,3 
216 2085-2103 VAAEEYVEVTRVGDFHYVT 2/20 5.2; 5.5 
218 2126-2145 DGVRLHRYAPVCKPLLREEV 1/20 4,4 
220 2157-2176 GSQ LPCE PE PDVAVLTS M L 4/20 17.5 (13.0-26.6) 
221 2169-2188 AVLTSM LTDPSHITAETAKR 2/20 12.3; 19.9 
222 2182- 2200 TAETAKRRLARGSPPSLAS 1/20 5,3 
223 2190-2208 LARGSPPSLASSSASQLSA 2/20 10.9; 19.1 
224 2202- 2221 SASQ LSAPSLKATCq-I-H H DS 1/20 6.3 
226 2220- 2238 DS PDADLI EAN LLWRQ EM G 1/20 4.1 
231 2271-2290 PAEILRKPRKFPPALPIWAR 8/20 44.9 (5.0-114.7) 
232 2279-2298 RKFPPALPtWARPDYN PPLL 4/20 31.5 (11,8-81.0) 
233 2295-2313 PPLLESWKDPDYVPPWHG 10/20 24.9 (4.1-96.4) 
234 2313-2332 GCPLPSTKAPPIPPPRRKRT 3/20 30.6 (11.6-49.0) 
235 2336-2354 TESTVSSALAELATKTFGS 2/20 12.8; 16.0 
236 2346-2365 ELATKTFGSSGSSAVDSGTA 1/20 10.1 
237 2353-2372 GSSGSSAVDSGTATGPPDQA 2/20 4.7; 5,9 
240 2374- 2392 DDG DKGSDVESYSSM PPLE 1/20 15.9 
241 2377-2396 DKGSDVESYSSMPPLEGEPG 1/20 17.9 
242 2381-2400 DVESYSSMPPLEGEPGDPDL 8.20 14.0 (4.0-34.7) 
243 2385-2404 YSSMPPLEGEPGDPDLSDGS 8/20 13.9 (3.4-40.8) 
244 2390-2409 PLEGEPGDPDLSDGSWSTVS 6/20 13,4 (4.2-31.0) 
247 2434-2452 AAEESKLPINPLSNSLLRH 7/20 11.4 (3.7-31.7) 
248 2460-2479 TSRSASLRQKKVTFDRLQVL 1/20 6 
250 2505-2523 EEACKLTPPHSAKSKFGYG 1/20 22.9 
255 2607-2626 GPSYGFQYSPGQRVEFLVNT 1/20 4.5 
258 2681-2699 VGGPLTNSKGQNCGYRRCR 1/20 8.1 
259 2717-2735 KATAACRAAKLQDCTM LVN 4/20 11.6 (4.4-17.9) 
260 2744-2763 ESAGTQEDAAALRAFTEAMT 1/20 8.1 
261 2760-2778 EAMTRYSAPPGDPPQPEYD 1/20 8.9 
267 2894-2913 HSYSPGEINRVASCLRKLGV 7/20 12.9 (6.4-33.6) 
a,b See the legend to Table 1. 
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TABLE 3 
IMMUNOREACTJV[TY OF SYNTHETIC PEPTIDES FROM THE NS9 AND NS4 PROTEINS WITH iNDIVIDUAL SERA 
66g 
Serum specimens 
Region Peptide 65 66 67 68 71 72 73 74 75 76 77 78 80 81 83 84 85 86 87 88 
NS3 99 C 
9b C 
107 B A 
117 C 
60 D D 
NS4 50 C E C D D E C B 
51 B D B C D D D C B 
52 B C A C D 
53 B B A C B B E B E 
54 B 
57 D 
59 F B C D E B D F E F F F B D F B C F 
Note. A, P/N = 3.0-4.9; B, P/N = 5.0-9.9; C, P/N = 10.0-19.9; D, P/N = 20.0-29.9; E, P/N = 30,0-49.9; F, P/N > 50.0. 
In terms of antigenic reactivity modeled with synthetic 
peptides, the NS4 protein is much more reactive than 
the NS3 protein. Of 20 synthetic peptides examined, 7 
demonstrated strong immunoreactivity (Table 1). Five of 
these, peptides 50, 51, 52, 53, and 54, are located in the 
5-1-1 region which has been shown to contain strong 
antigenic reactivity (14). Since peptides 50 and 53 are 
not overlapped (Table 1), the 5-1-1 region contains at 
least two linear epitopes. After analyzing the sequences 
of these peptides and the pattern of reactivity with differ- 
ent anti-HCV-positive sera (Table 3), we conclude that 
peptides 50, 51, and 52 share one antigenic epitope and 
peptides 53 and 54 share another epitope, and the com- 
mon region within each of these peptide groups may 
represent the actual antigenic epitope or an essential 
element of the epitope. Thus, the 5-1-1 region may con- 
tain two epitopes, one located at position 1701-1708 aa 
with the sequence LYREFDEM, and the other located at 
position 1721-1730 aa with the sequence GMMLAE- 
QFKQ. Similarly, two antigenic epitopes were recently 
found in the 5-1-1 region using monoclonal antibodies 
and synthetic peptides (31, 33). 
In addition to epitopes in the 5-1-1 region, we found 
two more immunoreactive peptides in the NS4 protein 
(Tables 1 and 3). One marginally reactive peptide, 57, is 
positioned inside the O100-3 region. Another peptide, 59, 
containing the most broadly reactive antigenic epitope 
found in this study, overlaps with the C-terminal region 
of C100-3. To analyze this antigenic region in more detail, 
we synthesized an additional small set of nine peptides 
sPanning the sequence of the NS4 protein at position 
1905-1955 aa (Fig. 2). These peptides were examined 
1905 1910 1920 1930 1940 1950 1955 
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FIG. 2. Identification of the antigenic epitope located within peptide 59, Primary structure of the HCV polyprotein region at position 1905 1955 
aa (4) and the amino acid sequence of synthetic peptides 59 and 134 142 are shown, The degree of immunoreactivity is indicated by the thickness 
of the horizontal bars. The numbers in parentheses show how many immunoreactive serum specimens were found for each peptide of 12 anti- 
HOV-positive sera analyzed. The sequence common for all immunoreactive peptides identified within this region is framed and shadowed. 
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TABLE 4 
REACTIVITY OF SYNTHETIC PEPTIDES FROM THE NS5 PROTEIN WITH INDIVIDUAL SERA 
Serum specimens 
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Note. A, P/N = 3.0-4.9; B, P/N = 5.0-9.9; C, P/N = 10.0-19.9; D, P/N = 20.0-29.9; E, P/N = 30.0-49.9; F, P/N > 50.0. 
for antigenic reactivity with 12 anti-HCV-positive sera se- 
lected from the panel used in this study. Peptides 137, 
138, 139, and 140 were immunoreactive in addition to 
peptide 59 (Fig. 2). The only common region shared by 
these immunoreactive peptides is the sequence SPTHYV 
located at position 1930-1935 aa. Therefore, this region 
appears to be the antigenic epitope located within pep- 
tide 59, which is located outside of the C100-3 region. 
Thus, we found at least four antigenic epitopes within 
the NS4 protein with 1 epitepe located within NS4a (Fig. 
1 and Table 1; peptides 50, 51, and 52) and three epitopes 
within NS4b (Fig. 1 and Table 1; one within peptides 
53 and 54, one within peptide 57, and one within pep- 
tide 59). 
The results of the analysis of the antigenic properties 
of 68 synthetic peptides prepared from the NS5 protein 
are shown in Tables 2 and 4. We found 30 peptides 
demonstrating HCV-specific immunoreactivity, repre- 
senting almost 45% of all NS5 peptides examined in this 
study. However, 19 peptides reacted with only one or 
two anti-HCV-positive sera (Tables 2 and 4). Peptides 
212, 218, 226, and 255 reproducibly bound an antibody 
from different single specimens with consistently low 
P/N values equal to 4.1-4.5. We did not find any exam- 
ples of reactivity to these peptides with anti-HOV-nega- 
tive sera and, therefore, considered these peptides to- 
gether with other weakly reactive peptides as marginally 
immunoreactive. Very few publications describe epitopes 
within the HCV NS5 protein. Two antigen epitopes have 
been recently identified by Yuki et aL (28). One epitope 
was found at position 2373-2386 aa and the second 
epitope was found at position 2467-2486 aa. Both of 
these epitopes were also identified in our study as mar- 
ginally reactive (Table 2, peptides 240 and 248), 
Recently, an additional protease cleavage site was 
identified within the HCV NS5 protein, dividing it into 
halves, with the N-terminal half named NSSa of unknown 
function(s) and the C-terminal half named NSSb and pos- 
sibly representing the RNA-dependent RNA polymerase 
(39). Twenty-one immunoreactive peptides (70% of all 
immunoreactive NS5 peptides) are located within the 
NS5a protein (Table 2, peptides 212-244), while only 9 
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peptides (30% of all immunoreactive NS5 peptides) are 
located within the NS5b (Table 2, peptides 247-267). 
In total, 38 peptides were prepared from NS5a and 30 
peptides from the NS5b. Therefore, without regard to the 
breadth of immunoreactivity, 55% of peptides prepared 
from NS5a and 30% of peptides prepared from NS5b 
contain linear antigenic epitopes modeled with short 
peptides, indicating that the NS5a region is very immuno- 
reactive. For comparison, only 7.5% of the NS3 peptides 
and 35% of the NS4 peptides had HOV-specific antigenic 
reactivity. Taking into consideration the location of pep- 
tides and the pattern of reactivity of these peptides with 
different anti-HCV sera (Table 4), 24 B-cell epitopes may 
be identified within the NS5 protein, with 15 epitopes 
located within NS5a and 9 epitopes within NS5b. Each 
NS5b immunoreactive synthetic peptide seems to have 
its own antigenic epitope (Table 2). Within NS5a, how- 
ever, peptides 223 and 224; 231 and 232; 235 and 236; 
240 and 241; and 242, 243, and 244 appear to share B- 
cell epitopes within each group (Table 2). The remaining 
10 epitopes are located within individual peptides (Table 
2). In the NS5a protein, four antigenic epitopes were 
reactive with 25-50% of anti-HOV-positive sera (Table 2); 
the first epitope is located within peptide 220, the second 
is shared by peptides 231 and 232, the third is repre- 
sented within peptide 233, and the fourth is shared by 
overlapped peptides 242, 243, and 244. The NS5b region 
has three strong epitopes (Table 2; peptide 247, 259, 
267). Collectively, peptides containing these strong 
broadly reactive epitopes interact with 16 of 20 anti-HOV- 
positive sera used in this study. The two sera that did 
not react with NS3 and NS4 synthetic peptides also did 
not react with any peptide derived from NS5 protein (Ta- 
bles 3 and 4). Nonetheless, antigenic epitopes located 
within the NS5 protein frequently elicit antibodies during 
the course of HCV infection, suggesting that these epi- 
topes may have significant value as diagnostic reagents 
for the development of HOV-specific tests. 
Finally, significant variation in the primary structure of 
the HOV proteins has been reported (4-13). Obviously, 
sequence variation may affect the immunoreactivity of 
many of the antigenic epitopes identified in this study. 
For a more complete understanding of the antigenic or- 
ganization of the HCV polyprotein, peptides derived from 
different HCV strains should be prepared and analyzed. 
Such an analysis is currently under investigation. 
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